Physician profile
Michael Kwok
NPI 1881717197
$717.84
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2021: $70.30 · 2022: $17.12.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $262.56 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.46 | 2019 | |
| Abbvie INC. | $87.42 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $51.03 | 2019 | |
| Amgen INC. | $44.63 | 2019 | |
| Novo Nordisk INC | $35.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $32.00 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.31 | 2019 | |
| Amarin Pharma, INC. | $17.83 | 2019 | |
| Arbor Pharmaceuticals, INC. | $16.27 | 2019 | |
| Allergan, INC. | $15.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kwok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.